ProtoKinetix, Incorporated

Equities

PKTX

US7437221002

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:58:45 2024-05-09 pm EDT			5-day change	1st Jan Change
0.0164 ^USD	+4.93%		+5.13%	-13.68%

Mar. 29	ProtoKinetix, Incorporated announced a financing transaction	CI
Mar. 20	ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ProtoKinetix Inc. Appoints Peter K. Jensen as Director

February 26, 2015 at 08:00 am EST

ProtoKinetix Inc. announced that Peter K. Jensen, Chairman of RepliCel Life Sciences and practicing lawyer, was appointed to the company's board of directors. In addition to continuing an active legal practice at Beadle Raven LLP, Mr. Jensen is Chairman of RepliCel Life Sciences. Mr. Jensen is Chairman of Solar Flow-Through Limited Partnerships I, II, III and IV which are installing solar power arrays in Ontario under the Ontario FIT program.

Mr. Jensen is also a director of a British Columbia public agricultural land banking company, New Age Farms, and of a California public company, bBooth Inc, offering music booth recording facilities to the public.

Latest news about ProtoKinetix, Incorporated

ProtoKinetix, Incorporated announced a financing transaction	Mar. 28	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.11 million in funding	Dec. 25	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-18	CI
ProtoKinetix, Incorporated announced that it has received $0.03 million in funding	23-08-28	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-14	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	23-05-24	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	23-05-24	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
ProtoKinetix, Incorporated Auditor Raises 'Going Concern' Doubt	23-03-16	CI
ProtoKinetix, Incorporated announced that it has received $0.04 million in funding	23-01-22	CI
ProtoKinetix, Incorporated announced a financing transaction	22-12-29	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.037 million in funding	22-12-29	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.063 million in funding	22-12-08	CI
ProtoKinetix, Incorporated announced a financing transaction	22-12-07	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI
ProtoKinetix, Incorporated announced that it has received funding	22-10-13	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-29	CI
ProtoKinetix, Incorporated Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants	22-07-20	CI
ProtoKinetix, Incorporated announced a financing transaction	22-07-10	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.2 million in funding	22-07-10	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
ProtoKinetix, Incorporated announced that it has received $0.05 million in funding	22-03-17	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-10	CI
ProtoKinetix, Incorporated Auditor Raises 'Going Concern' Doubt	22-03-09	CI

Chart ProtoKinetix, Incorporated

Duration

Period

More charts

Company Profile

ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Companyâs anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. In a clinical setting, AAGP is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time. The Company has not developed a commercially viable product and has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTOKINETIX, INCORPORATED	-13.68%	5.79M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+46.45%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research